Hepamerz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## Hepamerz (L-Ornithine L-Aspartate) ### Overview Hepamerz is a combination of two amino acids, L-ornithine and L-aspartate, used in the management of hyperammonemia associated with liver insufficiency. ### Primary Indications * Treatment of latent and manifest hepatic encephalopathy. ### Adult Dosing * **Oral:** 3 to 6 grams three times daily. * **Intravenous:** Typically 5 grams twice daily as an infusion over 30-60 minutes. Specific infusion rates and total daily doses may vary based on clinical status and local protocols. ### Pediatric Dosing * Dosing in pediatric patients is not well-established and should be individualized based on clinical response and physician judgment. ### Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is metabolized by the liver and excreted renally. However, caution is advised in severe renal impairment. ### Contraindications * Severe renal insufficiency (creatinine clearance < 25 mL/min). * Hypersensitivity to L-ornithine or L-aspartate. * Rare hereditary conditions such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should be considered for oral formulations containing sucrose. ### Adverse Effects * Nausea, vomiting, abdominal discomfort, diarrhea. * Rare: headache, dizziness, fatigue. * Skin rash and itching (hypersensitivity). ### Key Drug Interactions * No significant drug interactions have been widely reported. ### Monitoring * Monitor for improvement in symptoms of hepatic encephalopathy (e.g., cognitive function, confusion). * Monitor electrolytes and renal function, especially in patients with pre-existing conditions or receiving IV therapy. ### Clinical Pearls * Ornithine and aspartate are thought to help in ammonia detoxification by stimulating the urea cycle and glutamine synthesis, respectively. * Oral administration may be less effective or slower to act than intravenous administration in acute encephalopathy. * IV administration should be slow to minimize risk of local irritation or phlebitis. *** *Disclaimer: This information is intended for healthcare professionals and is a summary of essential drug information. Always refer to the most current prescribing information and consult with a clinical pharmacist or other healthcare provider for complete details and to ensure patient-specific appropriateness.*